PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. Its lead product candidates comprise PGN-EDO51, an EDO peptide which is Phase 2 clinical trial to treat duchenne muscular dystrophy (DMD) patients that are amenable to an exon 51-skipping approach; PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and PGN-EDO53, which is in preclinical trial to treat duchenne muscular dystrophy. The company was founded in 2018 and is based in Boston, Massachusetts.
Metrics to compare | PEPG | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipPEPGPeersSector | |
---|---|---|---|---|
P/E Ratio | −3.5x | −2.3x | −0.7x | |
PEG Ratio | −0.37 | 0.08 | 0.00 | |
Price/Book | 4.7x | 2.0x | 2.6x | |
Price / LTM Sales | - | 3.4x | 3.4x | |
Upside (Analyst Target) | 84.0% | 111.4% | 39.1% | |
Fair Value Upside | Unlock | 16.8% | 5.3% | Unlock |